Company Compass Therapeutics, Inc. OTC Markets
Equities
CMPX
US20454B1044
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -10.80% | +32.67% | -.--% |
05-13 | Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-06 | Top Premarket Gainers | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 31/12/16 | |
Thomas Schuetz
FOU | Founder | 63 | 31/12/13 |
Neil Lerner
DFI | Director of Finance/CFO | 56 | 31/12/19 |
Karin Herrera
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/22 |
Minori Rosales
CTO | Chief Tech/Sci/R&D Officer | 61 | 30/04/23 |
General Counsel | - | 31/07/21 | |
Ian Chia
PRN | Corporate Officer/Principal | - | 31/12/17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Lindahl
BRD | Director/Board Member | 70 | 20/04/23 |
Mary Gray
BRD | Director/Board Member | 71 | 24/04/22 |
Ellen Chiniara
BRD | Director/Board Member | 65 | 24/04/22 |
Carl Gordon
CHM | Chairman | 59 | 31/12/14 |
Phil Ferneau
BRD | Director/Board Member | 62 | 31/12/14 |
Thomas Schuetz
FOU | Founder | 63 | 31/12/13 |
James Boylan
BRD | Director/Board Member | 57 | 31/10/22 |
Chief Executive Officer | 53 | 31/12/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 137,589,171 | 121,022,398 ( 87.96 %) | 0 | 87.96 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.29% | 114B | |
+10.21% | 104B | |
+0.41% | 22.28B | |
-11.90% | 22.41B | |
-5.99% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- CMPX Stock
- CMPX Stock
- Company Compass Therapeutics, Inc.